These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30859582)

  • 1. Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.
    Caussy C; Bhargava M; Villesen IF; Gudmann NS; Leeming DJ; Karsdal MA; Faulkner C; Bao D; Liu A; Lo MT; Bettencourt R; Bassirian S; Richards L; Brenner DA; Chen CH; Sirlin CB; Loomba R
    Hepatology; 2019 Jul; 70(1):127-141. PubMed ID: 30859582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
    Caussy C; Soni M; Cui J; Bettencourt R; Schork N; Chen CH; Ikhwan MA; Bassirian S; Cepin S; Gonzalez MP; Mendler M; Kono Y; Vodkin I; Mekeel K; Haldorson J; Hemming A; Andrews B; Salotti J; Richards L; Brenner DA; Sirlin CB; Loomba R;
    J Clin Invest; 2017 Jun; 127(7):2697-2704. PubMed ID: 28628033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.
    Loomba R; Schork N; Chen CH; Bettencourt R; Bhatt A; Ang B; Nguyen P; Hernandez C; Richards L; Salotti J; Lin S; Seki E; Nelson KE; Sirlin CB; Brenner D;
    Gastroenterology; 2015 Dec; 149(7):1784-93. PubMed ID: 26299412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Caussy C; Hsu C; Lo MT; Liu A; Bettencourt R; Ajmera VH; Bassirian S; Hooker J; Sy E; Richards L; Schork N; Schnabl B; Brenner DA; Sirlin CB; Chen CH; Loomba R;
    Hepatology; 2018 Sep; 68(3):918-932. PubMed ID: 29572891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.
    Ajmera V; Liu A; Bettencourt R; Dhar D; Richards L; Loomba R
    Aliment Pharmacol Ther; 2021 Jul; 54(1):68-77. PubMed ID: 33975381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD.
    Cohen CC; Castillo-Leon E; Farris AB; Caltharp SA; Cleeton RL; Sinclair EM; Shevell DE; Karsdal MA; Nielsen MJF; Leeming DJ; Vos MB
    Hepatol Commun; 2021 Nov; 5(11):1860-1872. PubMed ID: 34558828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Ajmera VH; Liu A; Singh S; Yachoa G; Ramey M; Bhargava M; Zamani A; Lopez S; Mangla N; Bettencourt R; Rizo E; Valasek M; Behling C; Richards L; Sirlin C; Loomba R
    Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data.
    Andersen G; Plum-Mörschel L; Hockings PD; Morsing A; Palle MS; Svolgaard O; Flint A
    Adv Ther; 2020 Dec; 37(12):4866-4876. PubMed ID: 33006125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
    Park JG; Jung J; Verma KK; Kang MK; Madamba E; Lopez S; Qas Yonan A; Liu A; Bettencourt R; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2021 May; 53(9):1030-1037. PubMed ID: 33764550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of Virtual MR Elastography With Diffusion-Weighted Imaging in Subjects With Nonalcoholic Fatty Liver Disease.
    Hanniman E; Costa AF; Bowen CV; Abdolell M; Stueck A; McLeod M; Peltekian K; Rioux J; Clarke SE
    J Magn Reson Imaging; 2022 Nov; 56(5):1448-1456. PubMed ID: 35285996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.